Pharmafile Logo
Pharmafocus logo
Advanced Search

Forest

Showing 10 posts of 10 posts found.

Actavis image

Actavis to axe 200 jobs

December 4, 2014
Medical Communications, Sales and Marketing Actavis, Allergan, Forest, GSK, Warner Chilcott, corona, stevenage

Actavis is set to cut 200 jobs in the US just weeks after buying Allergan for $66 billion. The lay-offs …

News
Allergan image

Allergan and Valeant trade blows as shareholder meeting looms

November 6, 2014
Sales and Marketing Actavis, Allergan, Forest, Valeant, merger, warner

Allergan’s efforts to block a key supporter of Valeant’s hostile takeover bid from voting at next month’s special shareholder meeting …

News
Forest image

Forest sold to Actavis for $25 billion

February 18, 2014
Sales and Marketing Actavis, CNS, Forest, acquisition, labs, merger, synergy

The rumours of a substantial deal for Forest have been proven true after Actavis announced this afternoon that it will …

News
Aptalis image

Forest to buy Aptalis for $2.9 billion

January 9, 2014
Sales and Marketing Forest, aptlias, canasa, maris

Forest Laboratories will spend around $2.9 billion to purchase Aptalis, a privately-held US firm specialising in treatments for gastrointestinal disorders …

News
Forest labs image

FDA approves Forest’s COPD drug

July 25, 2012
Sales and Marketing COPD, FDA, Forest, Tudorza Pressair

US regulators have approved Forest Laboratories’ new chronic obstructive pulmonary disease (COPD) drug. Tudorza Pressair (aclidinium bromide) has been given …

News

Forest’s COPD drug approved in US

March 3, 2011
Sales and Marketing COPD, Daliresp, Daxas, Forest, Forest Laboratories, chronic obstructive pulmonary disease, roflumilast

Daliresp (roflumilast) has been approved by the FDA to treat severe chronic obstructive pulmonary disease. Forest Laboratories’ once-daily pill is …

News

Forest depression candidate struggles against placebo

March 1, 2011
Research and Development Forest, Forest Laboratories, Gedeon Richter, cariprazine, depression, major depressive disorder

An investigational antipsychotic drug being developed by Forest Laboratories and Budapest-based Gedeon Richter has failed to prove itself in phase …

News

Almirall and Forest’s phase III COPD drug misses goal

November 3, 2010
Research and Development Aclidinium bromide, Almirall, COPY, Forest, Forest Laboratories, chronic obstructive pulmonary disease

Almirall and Forest’s COPD drug aclidinium bromide has disappointed in a phase III trial by producing fewer benefits than found …

News

AstraZeneca signs deals to increase anti-infective portfolio

January 7, 2010
Research and Development, Sales and Marketing AstraZeneca, Forest, Novexel

AstraZeneca is to buy infection research firm Novexel for $350 million. The manufacturer will take all the French company’s shares …

News

AZ signs antibiotic deal with Forest Laboratories

August 13, 2009
Research and Development, Sales and Marketing Antibiotics, Forest

AstraZeneca has struck a deal with Forest Laboratories to co-develop and commercialise ceftaroline, an anti-infective drug in phase III. The …

News

Latest content

Sanofi shares results from phase 2 trial for frexalimab in MS treatment

July 1, 2024

EMA accepts AstraZeneca’s regulatory submission for sipavibart for COVID-19 prevention

July 1, 2024

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024